Bismuth-213 for targeted radionuclide therapy: from atom to bedside.

Phase 3 Trial of ¹⁷⁷ Lu-Dotatate for Midgut Neuroendocrine Tumors

Strosberg, J., El-Haddad, G., Wolin, E., Hendifar, A., Yao, J., Chasen, B., Mittra, E., Kunz, P. L., Kulke, M. H., Jacene, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1607427 · Cited by 3,308 · see citing works

Relativistic effects in structural chemistry

Pyykkö, P. (1988) · Chemical Reviews · doi:10.1021/cr00085a006 · Cited by 3,057 · see citing works

Hard and soft acids and bases, HSAB, part 1: Fundamental principles

Pearson, R. G. (1968) · Journal of Chemical Education · doi:10.1021/ed045p581 · Cited by 2,517 · see citing works

Engineered antibody fragments and the rise of single domains

Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,928 · see citing works

Matching chelators to radiometals for radiopharmaceuticals

Price, E. W., & Orvig, C. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60304k · Cited by 1,020 · see citing works

Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein

Lindner, T., Loktev, A., Altmann, A., Giesel, F. L., Kratochwil, C., Debus, J., Jäger, D., Mier, W., & Haberkorn, U. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210443 · Cited by 947 · see citing works

A Tumor-Imaging Method Targeting Cancer-Associated Fibroblasts

Loktev, A., Lindner, T., Mier, W., Debus, J., Altmann, A., Jäger, D., Giesel, F. L., Kratochwil, C., Barthe, P., Roumestand, C., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.210435 · Cited by 784 · see citing works

68 Ga-FAPI PET/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers

Giesel, F. L., Kratochwil, C., Lindner, T., Marschalek, M. M., Loktev, A., Lehnert, W., Debus, J., Jäger, D., Flechsig, P., Altmann, A., et al. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.215913 · Cited by 748 · see citing works

Bismuth Compounds and Preparations with Biological or Medicinal Relevance

Briand, G. G., & Burford, N. (1999) · Chemical Reviews · doi:10.1021/cr980425s · Cited by 599 · see citing works

MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of α-Particle Emitters for Targeted Radionuclide Therapy

Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., & Akabani, G. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.058651 · Cited by 552 · see citing works

Targeted α-Therapy of Metastatic Castration-Resistant Prostate Cancer with ²²⁵Ac-PSMA-617: Dosimetry Estimate and Empiric Dose Finding

Kratochwil, C., Bruchertseifer, F., Rathke, H., Bronzel, M., Apostolidis, C., Weichert, W., Haberkorn, U., Giesel, F. L., & Morgenstern, A. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.117.191395 · Cited by 505 · see citing works

Radioactive Main Group and Rare Earth Metals for Imaging and Therapy

Kostelnik, T. I., & Orvig, C. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00294 · Cited by 482 · see citing works

Targeted α particle immunotherapy for myeloid leukemia

Jurcic, J. G., Larson, S. M., Sgouros, G., McDevitt, M. R., Finn, R. D., Divgi, C. R., Ballangrud, Å., Hamacher, K. A., Ma, D., Humm, J. L., et al. (2002) · Blood · doi:10.1182/blood.v100.4.1233.h81602001233_1233_1239 · Cited by 472 · see citing works

213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience

Kratochwil, C., Giesel, F. L., Bruchertseifer, F., Mier, W., Apostolidis, C., Boll, R. A., Murphy, K., Haberkorn, U., & Morgenstern, A. (2014) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-014-2857-9 · Cited by 406 · see citing works

An Overview of Targeted Alpha Therapy with 225Actinium and 213Bismuth

Morgenstern, A., Apostolidis, C., Kratochwil, C., Sathekge, M. M., Królicki, L., & Bruchertseifer, F. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180502104524 · Cited by 371 · see citing works

Discovering and improving novel peptide therapeutics

MCGREGOR, D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.002 · Cited by 332 · see citing works

From molecules to bismuth oxide-based materials: Potential homo- and heterometallic precursors and model compounds

Mehring, M. (2006) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2006.06.005 · Cited by 293 · see citing works

Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA

Feuerecker, B., Tauber, R., Knorr, K., Heck, M. M., Beheshti, A., Seidl, C., Bruchertseifer, F., Pickhard, A., Gafita, A., Kratochwil, C., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.11.013 · Cited by 283 · see citing works

Coordination chemistry of metals in medicine: target sites for bismuth

Sadler, P. J., Li, H., & Sun, H. (1999) · Coordination Chemistry Reviews · doi:10.1016/s0010-8545(99)00018-1 · Cited by 280 · see citing works

Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

Rosenblat, T. L., McDevitt, M. R., Mulford, D. A., Pandit-Taskar, N. D., Divgi, C. R., Panageas, K. S., Heaney, M. L., Chanel, S. M., Morgenstern, A., Sgouros, G., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0382 · Cited by 272 · see citing works

Pleated Sheets and Turns of -Peptides with Proteinogenic Side Chains

Seebàch, D., Abele, S., Gademann, K., & Jaun, B. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19990601)38:11 · Cited by 268 · see citing works

Selective Inhibitors of Fibroblast Activation Protein (FAP) with a (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine Scaffold

Jansen, K., Heirbaut, L., Cheng, J. D., Joossens, J., Ryabtsova, O. V., Cos, P., Maes, L. J. R. M., Lambeir, A., Meester, I. D., Augustyns, K., et al. (2013) · ACS Medicinal Chemistry Letters · doi:10.1021/ml300410d · Cited by 264 · see citing works

A Critical Review of Alpha Radionuclide Therapy—How to Deal with Recoiling Daughters?

de Kruijff, R. M., Wolterbeek, H. T., & Denkova, A. G. (2015) · Pharmaceuticals · doi:10.3390/ph8020321 · Cited by 254 · see citing works

Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives

Parray, H. A., Shukla, S., Samal, S., Shrivastava, T., Ahmed, S., Sharma, C., & Kumar, R. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106639 · Cited by 225 · see citing works

Production of Ac-225 from Th-229 for Targeted α Therapy

Apostolidis, C., Molinet, R., Rasmussen, G., & Morgenstern, A. (2005) · Analytical Chemistry · doi:10.1021/ac0580114 · Cited by 215 · see citing works

Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial

Cordier, D., Forrer, F., Bruchertseifer, F., Morgenstern, A., Apostolidis, C., Good, S., Müller‐Brand, J., Mäcke, H. R., Reubi, J. C., & Merlo, A. U. (2010) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-010-1385-5 · Cited by 203 · see citing works

Development of ²²⁵Ac Radiopharmaceuticals: TRIUMF Perspectives and Experiences

Robertson, A. K. H., Ramogida, C. F., Schaffer, P., & Radchenko, V. (2018) · Current Radiopharmaceuticals · doi:10.2174/1874471011666180416161908 · Cited by 202 · see citing works

First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients

Zacherl, M. J., Gildehaus, F. J., Mittlmeier, L. M., Böning, G., Gosewisch, A., Wenter, V., Unterrainer, M., Schmidt-Hegemann, N.-S., Belka, C., Kretschmer, A., et al. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.120.251017 · Cited by 192 · see citing works

Cyclotron production of Ac-225 for targeted alpha therapy11Dedicated to Prof. Dr. Franz Baumgärtner on the occasion of his 75th birthday.

Apostolidis, C., Molinet, R., McGinley, J., Abbas, K., Möllenbeck, J., & Morgenstern, A. (2005) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2004.06.013 · Cited by 176 · see citing works

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Dekempeneer, Y., Keyaerts, M., Krasniqi, A., Puttemans, J., Muyldermans, S., Lahoutte, T., D’Huyvetter, M., & Devoogdt, N. (2016) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2016.1185412 · Cited by 171 · see citing works

Local Targeting of Malignant Gliomas by the Diffusible Peptidic Vector 1,4,7,10-Tetraazacyclododecane-1-Glutaric Acid-4,7,10-Triacetic Acid-Substance P

Kneifel, S., Cordier, D., Good, S., Ionescu, M.-C. S., Ghaffari, A., Höfer, S., Kretzschmar, M., Tolnay, M., Apostolidis, C., Waser, B., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2820 · Cited by 153 · see citing works

Design and Challenges of Radiopharmaceuticals

Vermeulen, K., Vandamme, M., Bormans, G. M., & Cleeren, F. (2019) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2019.07.001 · Cited by 152 · see citing works

213Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer

Sathekge, M. M., Knoesen, O., Meckel, M., Modiselle, M., Vorster, M., & Marx, S. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3657-9 · Cited by 147 · see citing works

Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617

Kratochwil, C., Schmidt, K. F., Afshar‐Oromieh, A., Bruchertseifer, F., Rathke, H. G., Morgenstern, A., Haberkorn, U., & Giesel, F. L. (2017) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-017-3817-y · Cited by 141 · see citing works

Supply and clinical application of Actinium-225 and Bismuth-213.

Morgenstern, A., Apostolidis, C., & Bruchertseifer, F. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.02.003 · Cited by 141 · see citing works

Transition metal compounds as cancer radiosensitizers

Gill, M. R., & Vallis, K. A. (2018) · Chemical Society Reviews · doi:10.1039/c8cs00641e · Cited by 139 · see citing works

An 225Ac/213Bi generator system for therapeutic clinical applications: construction and operation.

McDevitt, M. R., Finn, R. D., Sgouros, G., Ma, D., & Scheinberg, D. A. (1999) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(98)00151-1 · Cited by 138 · see citing works

Evaluation of the serum stability and in vivo biodistribution of CHX-DTPA and other ligands for yttrium labeling of monoclonal antibodies.

Camera, L., Kinuya, S., Garmestani, K., Wu, C., Brechbiel, M. W., Pai, L. H., McMurry, T. J., Gansow, O. A., Pastan, I. H., & Paik, C. H. (1994) · PubMed · Cited by 137 · see citing works

Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE for Patients With Somatostatin Receptor–Expressing Neuroendocrine Tumors

Delpassand, E. S., Samarghandi, A., Zamanian, S., Wolin, E. M., Hamiditabar, M., Espenan, G. D., Erion, J. L., O’Dorisio, T. M., Kvols, L. K., Simón, J., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000113 · Cited by 136 · see citing works

Bismuth-213 and Actinium-225 – Generator Performance and Evolving Therapeutic Applications of Two Generator-Derived Alpha-Emitting Radioisotopes

Morgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2012) · Current Radiopharmaceuticals · doi:10.2174/1874471011205030221 · Cited by 129 · see citing works

Intralesional targeted alpha therapy for metastatic melanoma

Allen, B., Raja, C., Rizvi, S. M., Li, Y., Tsui, W., Graham, P., Thompson, J. A., Reisfeld, R. A., Kearsley, J. H., Morgenstern, A., et al. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.12.2251 · Cited by 124 · see citing works

Synthesis of C-functionalized trans-cyclohexyldiethylenetriaminepenta-acetic acids for labelling of monoclonal antibodies with the bismuth-212 α-particle emitter

Brechbiel, M. W., & Gansow, O. A. (1992) · Journal of the Chemical Society Perkin Transactions 1 · doi:10.1039/p19920001173 · Cited by 115 · see citing works

Solvation of the Bismuth(III) Ion by Water, Dimethyl Sulfoxide,N,N‘-Dimethylpropyleneurea, andN,N-Dimethylthioformamide. An EXAFS, Large-Angle X-ray Scattering, and Crystallographic Structural Study

Näslund, J., Persson, I., & Sandström, M. (2000) · Inorganic Chemistry · doi:10.1021/ic000022m · Cited by 115 · see citing works

Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma

Raja, C., Graham, P., Rizvi, S. M., Song, E. Y., Goldsmith, H., Thompson, J. F., Bosserhoff, A., Morgenstern, A., Apostolidis, C., Kearsley, J. H., et al. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4089 · Cited by 110 · see citing works

Safety and efficacy of targeted alpha therapy with 213Bi-DOTA-substance P in recurrent glioblastoma

Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4225-7 · Cited by 109 · see citing works

Prolonged survival in secondary glioblastoma following local injection of targeted alpha therapy with 213Bi-substance P analogue

Królicki, L., Bruchertseifer, F., Kunikowska, J., Koziara, H. M., Królicki, B., Jakuciński, M., Pawlak, D., Apostolidis, C., Mirzadeh, S., Rola, R., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4015-2 · Cited by 108 · see citing works

Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200MeV

Weidner, J. W., Mashnik, S. G., John, K. D., Hemez, F., Ballard, B. D., Bach, H., Birnbaum, E. R., Bitteker, L. J., Couture, A. J., Dry, D., et al. (2012) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2012.07.006 · Cited by 101 · see citing works

The Biological and Medicinal Chemistry of Bismuth

Sun, H., Li, H., & Sadler, P. J. (1997) · Chemische Berichte · doi:10.1002/cber.19971300602 · Cited by 100 · see citing works

Zevalin® (ibritumomab tiuxetan): After more than a decade of treatment experience, what have we learned?

Rizzieri, D. A. (2016) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2016.07.008 · Cited by 100 · see citing works

Analysis of Patient Survival in a Phase I Trial of Systemic Targeted α-Therapy for Metastatic Melanoma

Allen, B., Singla, A. A., Rizvi, S. M. A., Graham, P., Bruchertseifer, F., Apostolidis, C., & Morgenstern, A. (2011) · Immunotherapy · doi:10.2217/imt.11.97 · Cited by 93 · see citing works

Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer

Juzeniene, A., Stenberg, V. Y., Bruland, Ø. S., & Larsen, R. H. (2021) · Cancers · doi:10.3390/cancers13040779 · Cited by 89 · see citing works

Bismuth speciation in hydrothermal fluids: An X-ray absorption spectroscopy and solubility study

Tooth, B., Etschmann, B. E., Pokrovski, G. S., Testemale, D., Hazemann, J., Grundler, P. V., & Brugger, J. (2012) · Geochimica et Cosmochimica Acta · doi:10.1016/j.gca.2012.10.020 · Cited by 86 · see citing works

Therapeutic peptides for cancer therapy. Part I – peptide inhibitors of signal transduction cascades

Bidwell, G. L., & Raucher, D. (2009) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903143745 · Cited by 85 · see citing works

Delivery of the α-emitting radioisotope bismuth-213 to solid tumors via single-chain Fv and diabody molecules

Adams, G. P., Shaller, C. C., Chappell, L. L., Wu, C., Horak, E. M., Simmons, H. H., Litwin, S., Marks, J. D., Weiner, L. M., & Brechbiel, M. W. (2000) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00103-7 · Cited by 83 · see citing works

Recent advances in theranostics and challenges for the future

Turner, J. H. (2018) · British Journal of Radiology · doi:10.1259/bjr.20170893 · Cited by 79 · see citing works

Mitigation of radiation nephropathy after internal α-particle irradiation of kidneys

Jaggi, J. S., Seshan, S. V., McDevitt, M. R., Sgouros, G., Hyjek, E. M., & Scheinberg, D. A. (2006) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2005.11.036 · Cited by 78 · see citing works

Treatment of carcinoma in situ of the urinary bladder with an alpha-emitter immunoconjugate targeting the epidermal growth factor receptor: a pilot study

Autenrieth, M. E., Seidl, C., Bruchertseifer, F., Horn, T. D., Kurtz, F., Feuerecker, B., D’Alessandria, C., Pfob, C. H., Nekolla, S. G., Apostolidis, C., et al. (2018) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4003-6 · Cited by 74 · see citing works

Equilibrium, 1H and 13C NMR Spectroscopy, and X-ray Diffraction Studies on the Complexes Bi(DOTA)- and Bi(DO3A-Bu)

Csajbók, É., Baranyai, Z., Bányai, I., Brücher, E., Király, R., Müller‐Fahrnow, A., Platzek, J., Radüchel, B., & Schäfer, M. (2003) · Inorganic Chemistry · doi:10.1021/ic0261272 · Cited by 73 · see citing works

Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease

Park, S. I., Shenoi, J., Pagel, J. M., Hamlin, D. K., Wilbur, D. S., Orgun, N. N., Kenoyer, A. L., Frayo, S. L., Axtman, A., Bäck, T. A., et al. (2010) · Blood · doi:10.1182/blood-2010-05-282327 · Cited by 73 · see citing works

213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model

Li, Y., Rizvi, S. M., Ranson, M., & Allen, B. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600179 · Cited by 73 · see citing works

Prognostic Significance of Somatostatin Receptor Heterogeneity in Progressive Neuroendocrine Tumor Treated with Lu-177 DOTATOC or Lu-177 DOTATATE

Graf, J., Pape, U., Jann, H., Denecke, T., Arsenić, R., Brenner, W., Pavel, M., & Prasad, V. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04439-9 · Cited by 73 · see citing works

Theranostic radionuclides: recent advances in production methodologies

Qaim, S. M. (2019) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-019-06797-y · Cited by 69 · see citing works

Investigation on the pharmacological profile of 2,6-diacetylpyridine bis(benzoylhydrazone) derivatives and their antimony(III) and bismuth(III) complexes

Ferraz, K. S. O., Silva, N. F., Silva, J. G. D., de Miranda, L. F., Romeiro, C. F. D., de Souza-Fagundes, E. M., Mendes, I. C., & Beraldo, H. D. O. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.03.040 · Cited by 68 · see citing works

Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand

Bruchertseifer, F., Kellerbauer, A., Malmbeck, R., & Morgenstern, A. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3792 · Cited by 68 · see citing works

Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine

Chan, H. S., Konijnenberg, M., Daniels, T., Nysus, M. V., Makvandi, M., de Blois, E., Breeman, W. A. P., Atcher, R. W., de Jong, M., & Norenberg, J. P. (2016) · EJNMMI Research · doi:10.1186/s13550-016-0240-5 · Cited by 67 · see citing works

Single-Dose Anti-CD138 Radioimmunotherapy: Bismuth-213 is More Efficient than Lutetium-177 for Treatment of Multiple Myeloma in a Preclinical Model

Fichou, N., Gouard, S., Maurel, C., Barbet, J., Ferrer, L., Morgenstern, A., Bruchertseifer, F., Faivre-Chauvet, A., Bigot‐Corbel, E., Davodeau, F., et al. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00076 · Cited by 64 · see citing works

Therapeutic Applications of Pretargeting

Verhoeven, M., Seimbille, Y., & Dalm, S. U. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090434 · Cited by 64 · see citing works

Synthesis, crystal structures, in vitro biological evaluation of zinc(II) and bismuth(III) complexes of 2-acetylpyrazine N(4)-phenylthiosemicarbazone

Li, M., Zhang, L., Yang, M., Niu, J., & Zhou, J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.02.024 · Cited by 61 · see citing works

Production of Ac-225 for cancer therapy by photon-induced transmutation of Ra-226

Melville, G., Meriarty, H., Metcalfe, P. E., Knittel, T., & Allen, B. (2007) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2007.03.018 · Cited by 61 · see citing works

Therapeutic Efficacy of 213Bi-labeled sdAbs in a Preclinical Model of Ovarian Cancer

Dekempeneer, Y., Caveliers, V., Ooms, M., Maertens, D., Gysemans, M., Lahoutte, T., Xavier, C., Lecocq, Q., Maes, K., Covens, P., et al. (2020) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.0c00580 · Cited by 60 · see citing works

Anti-CD45 pretargeted radioimmunotherapy using bismuth-213: high rates of complete remission and long-term survival in a mouse myeloid leukemia xenograft model

Pagel, J. M., Kenoyer, A. L., Bäck, T. A., Hamlin, D. K., Wilbur, D. S., Fisher, D. R., Park, S. I., Frayo, S. L., Axtman, A., Orgun, N. N., et al. (2011) · Blood · doi:10.1182/blood-2011-04-347039 · Cited by 59 · see citing works

Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor Cells

Drecoll, E., Gaertner, F. C., Miederer, M., Blechert, B., Vallon, M., Müller, J. M., Alke, A., Seidl, C., Bruchertseifer, F., Morgenstern, A., et al. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005715 · Cited by 57 · see citing works

Investigating the Complexation of the Pb2+/Bi3+ Pair with Dipicolinate Cyclen Ligands

Lima, L. M. P., Beyler, M., Delgado, R., Platas‐Iglesias, C., & Tripier, R. (2015) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.5b01079 · Cited by 57 · see citing works

Breakthrough of 225Ac and its radionuclide daughters from an 225Ac/213Bi generator: development of new methods, quantitative characterization, and implications for clinical use

Ma, D., McDevitt, M. R., Finn, R. D., & Scheinberg, D. A. (2001) · Applied Radiation and Isotopes · doi:10.1016/s0969-8043(01)00062-8 · Cited by 56 · see citing works

The affinity of bismuth(III) for nitrogen-donor ligands

Hancock, R. D., Cukrowski, I., Baloyi, J., & Mashishi, J. (1993) · Journal of the Chemical Society Dalton Transactions · doi:10.1039/dt9930002895 · Cited by 56 · see citing works

In Vivo Evaluation of Bismuth-Labeled Monoclonal Antibody Comparing DTPA-Derived Bifunctional Chelates

Milenic, D. E., Roselli, M., Mirzadeh, S., Pippin, C. G., Gansow, O. A., Colcher, D. M., Brechbiel, M. W., & Schlom, J. (2001) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/108497801300189227 · Cited by 56 · see citing works

Efficient Bifunctional Decadentate Ligand 3p-C-DEPA for Targeted α-Radioimmunotherapy Applications

Song, H. A., Kang, C. S., Baidoo, K. E., Milenic, D. E., Chen, Y., Dai, A., Brechbiel, M. W., & Chong, H. (2011) · Bioconjugate Chemistry · doi:10.1021/bc100586y · Cited by 56 · see citing works

Preclinical evaluation of NETA-based bifunctional ligand for radioimmunotherapy applications using 212Bi and 213Bi: Radiolabeling, serum stability, and biodistribution and tumor uptake studies

Kang, C. S., Song, H. A., Milenic, D. E., Baidoo, K. E., Brechbiel, M. W., & Chong, H. (2013) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2013.01.012 · Cited by 54 · see citing works

In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy

Chan, H. S., de Blois, E., Morgenstern, A., Bruchertseifer, F., de Jong, M., Breeman, W. A. P., & Konijnenberg, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0181473 · Cited by 53 · see citing works

Improved efficacy of α‐particle–targeted radiation therapy

Milenic, D. E., Brady, E. D., Garmestani, K., Albert, P. S., Abdulla, A., & Brechbiel, M. W. (2010) · Cancer · doi:10.1002/cncr.24793 · Cited by 52 · see citing works

α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen–Expressing Human Colon Cancer Xenografts

Heskamp, S., Hernandez, R., Molkenboer‐Kuenen, J. D. M., Essler, M., Bruchertseifer, F., Morgenstern, A., Steenbergen, E. J., Cai, W., Seidl, C., McBride, W. J., et al. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.187021 · Cited by 51 · see citing works

Targeting Aberrant DNA Double-Strand Break Repair in Triple-Negative Breast Cancer with Alpha-Particle Emitter Radiolabeled Anti-EGFR Antibody

Hong, S., Hedayati, M. A., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., DeWeese, T. L., & Sgouros, G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0108 · Cited by 50 · see citing works

Efficient synthesis and evaluation of bimodal ligand NETA

Chong, H., Song, H. A., Birch, N. W., Le, T., Lim, S., & Ma, X. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.084 · Cited by 49 · see citing works

α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma

Teiluf, K., Seidl, C., Blechert, B., Gaertner, F. C., Gilbertz, K.-P., Fernández‐Sáiz, V., Bassermann, F. C., Endell, J., Boxhammer, R., Leclair, S., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2986 · Cited by 49 · see citing works

Novel Bimodal Bifunctional Ligands for Radioimmunotherapy and Targeted MRI

Chong, H., Song, H. A., Ma, X., Milenic, D. E., Brady, E. D., Lim, S., Lee, H., Baidoo, K. E., Cheng, D., & Brechbiel, M. W. (2008) · Bioconjugate Chemistry · doi:10.1021/bc800050x · Cited by 46 · see citing works

Efficient formation of inert Bi-213 chelates by tetraphosphorus acid analogues of DOTA: towards improved alpha-therapeutics

Šimeček, J., Hermann, P., Seidl, C., Bruchertseifer, F., Morgenstern, A., Wester, H., & Notni, J. (2018) · EJNMMI Research · doi:10.1186/s13550-018-0431-3 · Cited by 43 · see citing works

In vitro and in vivo evaluation of novel ligands for radioimmunotherapy

Chong, H., Milenic, D. E., Garmestani, K., Brady, E. D., Arora, H., Pfiester, C. M., & Brechbiel, M. W. (2006) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2006.03.004 · Cited by 42 · see citing works

Radionuclide-Based Cancer Imaging Targeting the Carcinoembryonic Antigen

Hong, H., Sun, J., & Cai, W. (2008) · Biomarker Insights · doi:10.4137/bmi.s1124 · Cited by 41 · see citing works

111In-DTPA0-octreotide (Octreoscan), 131I-MIBG and other agents for radionuclide therapy of NETs

Bomanji, J. B., & Papathanasiou, N. D. (2012) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-011-2013-8 · Cited by 41 · see citing works

Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)

Ebbers, S. C., Braat, A. J. A. T., Moelker, A. D., Stokkel, M. P. M., Lam, M. G. E. H., & Barentsz, M. W. (2020) · Trials · doi:10.1186/s13063-019-3888-0 · Cited by 41 · see citing works

Combining α-Radioimmunotherapy and Adoptive T Cell Therapy to Potentiate Tumor Destruction

Ménager, J., Gorin, J., Maurel, C., Drujont, L., Gouard, S., Louvet, C., Chérel, M., Faivre-Chauvet, A., Morgenstern, A., Bruchertseifer, F., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130249 · Cited by 40 · see citing works

p-NO2–Bn–H4neunpa and H4neunpa–Trastuzumab: Bifunctional Chelator for Radiometalpharmaceuticals and 111In Immuno-Single Photon Emission Computed Tomography Imaging

Spreckelmeyer, S., Ramogida, C. F., Rousseau, J., Arane, K., Bratanovic, I., Colpo, N., Jermilova, U., Dias, G., Dude, I., Jaraquemada-Peláez, M. D. G., et al. (2017) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.7b00311 · Cited by 40 · see citing works

Cross sections from proton irradiation of thorium at 800 MeV

Engle, J. W., Mashnik, S. G., Weidner, J. W., Wolfsberg, L. E., Fassbender, M. E., Jackman, K. R., Couture, A. J., Bitteker, L. J., Ullmann, J. L., Gulley, M. S., et al. (2013) · Physical Review C · doi:10.1103/physrevc.88.014604 · Cited by 38 · see citing works

Evaluating the Combination of Radioimmunotherapy and Immunotherapy in a Melanoma Mouse Model

Jiao, R., Allen, K. J. H., Malo, M. E., Rickles, D. J., & Dadachova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21030773 · Cited by 38 · see citing works

Immunoliposomal Delivery of 213Bi for α-Emitter Targeting of Metastatic Breast Cancer

Lingappa, M., Hong, S., Thompson, S., Bruchertseifer, F., Morgenstern, A., & Sgouros, G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4548 · Cited by 36 · see citing works

Preferential Cleavage of a Tripeptide Linkage by Enzymes on Renal Brush Border Membrane To Reduce Renal Radioactivity Levels of Radiolabeled Antibody Fragments

Suzuki, C., Uehara, T., Kanazawa, N., Wada, S., Suzuki, H. Y., & Arano, Y. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00198 · Cited by 36 · see citing works

Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin’s lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003

Maaland, A. F., Saidi, A., Torgue, J. J.-C., Heyerdahl, H., Stallons, T. A. R., Kolstad, A., & Dahle, J. (2020) · PLoS ONE · doi:10.1371/journal.pone.0230526 · Cited by 36 · see citing works

Targeted alpha-therapy using [Bi-213]anti-CD20 as novel treatment option for radio- and chemoresistant non-Hodgkin lymphoma cells

Roscher, M., Hormann, I., Leib, O., Marx, S., Moreno, J., Miltner, E., & Friesen, C. (2013) · Oncotarget · doi:10.18632/oncotarget.817 · Cited by 34 · see citing works

A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line

Listek, M., Hönow, A., Gossen, M., & Hanack, K. (2020) · Scientific Reports · doi:10.1038/s41598-020-58571-w · Cited by 34 · see citing works

DTPA complexation of bismuth in human blood serum

Montavon, G., Du, A. L., Champion, J., Rabung, T., & Morgenstern, A. (2012) · Dalton Transactions · doi:10.1039/c2dt30230f · Cited by 33 · see citing works

Production of Alpha Emitters for Targeted Alpha Therapy

Morgenstern, A., Abbas, K., Bruchertseifer, F., & Apostolidis, C. (2008) · Current Radiopharmaceuticals · doi:10.2174/1874471010801030135 · Cited by 33 · see citing works

Targeted alpha and beta radiotherapy: An overview of radiopharmaceutical and clinical aspects

Lacœuille, F., Arlicot, N., & Faivre-Chauvet, A. (2018) · Médecine Nucléaire · doi:10.1016/j.mednuc.2017.12.002 · Cited by 33 · see citing works

Therapeutic Efficacy of Alpha-RIT Using a 213Bi-Anti-hCD138 Antibody in a Mouse Model of Ovarian Peritoneal Carcinomatosis

Derrien, A., Gouard, S., Maurel, C., Gaugler, M., Bruchertseifer, F., Morgenstern, A., Faivre-Chauvet, A., Classe, J., & Chérel, M. (2015) · Frontiers in Medicine · doi:10.3389/fmed.2015.00088 · Cited by 32 · see citing works

H2Me-do2pa: an attractive chelator with fast, stable and inert nat Bi 3+ and 213 Bi 3+ complexation for potential α-radioimmunotherapy applications

Lima, L. M. P., Beyler, M., Oukhatar, F., Saëc, P. L., Faivre-Chauvet, A., Platas‐Iglesias, C., Delgado, R., & Tripier, R. (2014) · Chemical Communications · doi:10.1039/c4cc05529b · Cited by 31 · see citing works

Radioimmunotherapy with Bismuth-213 as Conditioning for Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Dogs: A Dose Deescalation Study

Bethge, W. A., Wilbur, D. S., Storb, R. F., Hamlin, D. K., Santos, E. B., Brechbiel, M. W., & Sandmaier, B. M. (2004) · Transplantation · doi:10.1097/01.tp.0000128853.62545.b2 · Cited by 31 · see citing works

Synthesis and evaluation of a macrocyclic bifunctional chelating agent for use with bismuth radionuclides

Garmestani, K., Yao, Z., Zhang, M., Wong, K. J., Park, C., Pastan, I. H., Carrasquillo, J. A., & Brechbiel, M. W. (2001) · Nuclear Medicine and Biology · doi:10.1016/s0969-8051(00)00203-1 · Cited by 30 · see citing works

Structure-function analysis and therapeutic efficacy of antibodies to fungal melanin for melanoma radioimmunotherapy

Nosanchuk, J. D., Jeyakumar, A., Ray, A., Revskaya, E., Jiang, Z., Bryan, R. A., Allen, K. J. H., Jiao, R., Malo, M. E., Gómez, B. L., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-23889-z · Cited by 30 · see citing works

Synthesis and biological evaluation of a novel decadentate ligand DEPA

Chong, H., Lim, S., Baidoo, K. E., Milenic, D. E., Ma, X., Jia, F., Song, H. A., Brechbiel, M. W., & Lewis, M. R. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.09.063 · Cited by 28 · see citing works

Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in preclinical targeted alpha therapy for cancer

Song, E. Y., Rizvi, S. M., Qu, C. F., Raja, C., Brechbiel, M. W., Morgenstern, A., Apostolidis, C., & Allen, B. (2007) · Cancer Biology & Therapy · doi:10.4161/cbt.6.6.4097 · Cited by 28 · see citing works

Evaluation of Met-Val-Lys as a Renal Brush Border Enzyme-Cleavable Linker to Reduce Kidney Uptake of 68Ga-Labeled DOTA-Conjugated Peptides and Peptidomimetics

Bendre, S., Zhang, Z., Kuo, H., Rousseau, J., Zhang, C., Merkens, H., Roxin, Á., Bénard, F., & Lin, K. (2020) · Molecules · doi:10.3390/molecules25173854 · Cited by 28 · see citing works

Phase I trial of α-particle therapy with actinium-225 (225Ac)-lintuzumab (anti-CD33) and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML.

Jurcic, J. G., Ravandi, F., Pagel, J. M., Park, J. H., Smith, B. D., Douer, D., Levy, M. Y., Estey, E. H., Kantarjian, H. M., Earle, D. C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.7050 · Cited by 27 · see citing works

Targeted Alpha-Particle Therapy for Hematologic Malignancies

Jurcic, J. G. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.05.008 · Cited by 27 · see citing works

Fractionated intravesical radioimmunotherapy with213Bi-anti-EGFR-MAb is effective without toxic side-effects in a nude mouse model of advanced human bladder carcinoma

Fazel, J., Rötzer, S., Seidl, C., Feuerecker, B., Autenrieth, M. E., Weirich, G., Bruchertseifer, F., Morgenstern, A., & Senekowitsch–Schmidtke, R. (2015) · Cancer Biology & Therapy · doi:10.1080/15384047.2015.1071735 · Cited by 26 · see citing works

Different ways to improve the clinical effectiveness of radioimmunotherapy in solid tumors

Chatal, J., Davodeau, F., Chérel, M., & Barbet, J. (2009) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.55139 · Cited by 25 · see citing works

Synthesis and evaluation of a bifunctional chelate for development of Bi(III)-labeled radioimmunoconjugates

Dadwal, M., Kang, C. S., Song, H. A., Sun, X. Y., Dai, A., Baidoo, K. E., Brechbiel, M. W., & Chong, H. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.107 · Cited by 21 · see citing works

Long-Term Toxicity of 213Bi-Labelled BSA in Mice

Dorso, L., Bigot‐Corbel, E., Abadie, J., Diab, M., Gouard, S., Bruchertseifer, F., Morgenstern, A., Maurel, C., Chérel, M., & Davodeau, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0151330 · Cited by 20 · see citing works

Therapeutic efficacy of α-radioimmunotherapy with different activity levels of the 213Bi-labeled monoclonal antibody MX35 in an ovarian cancer model

Gustafsson-Lutz, A., Bäck, T. A., Aneheim, E., Hultborn, R., Palm, S., Jacobsson, L., Morgenstern, A., Bruchertseifer, F., Albertsson, P., & Lindegren, S. (2017) · EJNMMI Research · doi:10.1186/s13550-017-0283-2 · Cited by 20 · see citing works

Measurement of the Beam Energy Distribution of a Medical Cyclotron with a Multi-Leaf Faraday Cup

Nesteruk, K. P., Ramseyer, L., Carzaniga, T. S., & Braccini, S. (2019) · Instruments · doi:10.3390/instruments3010004 · Cited by 18 · see citing works

Targeted Alpha Therapy Approach to the Management of Pancreatic Cancer

Allen, B., Rizvi, S. M., Qu, C. F., & Smith, R. C. (2011) · Cancers · doi:10.3390/cancers3021821 · Cited by 16 · see citing works

213Bi production and complexation with new picolinate containing ligands

Sinenko, I. L., Калмыкова, Т. П., Likhosherstova, D. V., Egorova, B. V., Zubenko, A. D., Vasiliev, A. N., Ermolaev, S. V., Lapshina, E. V., Ostapenko, V. S., Fedorova, O. A., et al. (2019) · Journal of Radioanalytical and Nuclear Chemistry · doi:10.1007/s10967-019-06610-w · Cited by 16 · see citing works

A Radiolabeled Fully Human Antibody to Human Aspartyl (Asparaginyl) β -Hydroxylase Is a Promising Agent for Imaging and Therapy of Metastatic Breast Cancer

Revskaya, E., Jiang, Z., Morgenstern, A., Bruchertseifer, F., Sesay, M. A., Walker, S., Fuller, S. A., Lebowitz, M., Gravekamp, C., Ghanbari, H. A., et al. (2017) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2016.2141 · Cited by 11 · see citing works

Evaluation of novel highly specific antibodies to cancer testis antigen Centrin‐1 for radioimmunoimaging and radioimmunotherapy of pancreatic cancer

Jiao, R., Allen, K. J. H., Malo, M. E., Helal, M. H. S., Jiang, Z., Smart, K., Buhl, S., Rickles, D. J., Bryan, R. A., & Dadachova, E. (2019) · Cancer Medicine · doi:10.1002/cam4.2379 · Cited by 11 · see citing works

High-Purity Actinium-225 Production from Radium-226 using a Superconducting Electron Linac

Grimm, T., Grimm, A. K., Peters, W. A., & Zamiara, M. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.03.040 · Cited by 9 · see citing works

The hydrothermal chemistry of Bismuth and the liquid Bismuth collector model.

Tooth, B. (2013) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · Cited by 9 · see citing works

Could Autoimmune Disease Contribute to the Abscopal Effect in Metastatic Hepatocellular Carcinoma?

Beyls, C., Haustermans, K. M., Deroose, C. M., Pans, S., Vanbeckevoort, D., Verslype, C., & Dekervel, J. (2020) · Hepatology · doi:10.1002/hep.31186 · Cited by 9 · see citing works

Thorium-229 quantified in historical Thorium-228 capsules

Boden, S., Koen, V., Cagno, S., Maertens, D., Hecke, K. V., & Cardinaels, T. (2016) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2016.11.012 · Cited by 7 · see citing works

Assessment of 213Bi-anti-EGFR MAb treatment efficacy in malignant cancer cells with [1-13C]pyruvate and [18F]FDG

Feuerecker, B., Michalik, M., Hundshammer, C., Schwaiger, M., Bruchertseifer, F., Morgenstern, A., & Seidl, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-44484-w · Cited by 7 · see citing works

Proton-induced cross sections relevant to production of 225Ac and 223Ra in natural thorium targets below 200 MeVPreprint

Weidner, J. W., Mashnik, S. G., John, K. D., et al. (2012) · arXiv (Cornell University) · doi:10.48550/arxiv.1205.3523 · Cited by 4 · see citing works

A pulse radiolysis study of the chloride complexes of Bi(II) and Bi(IV)

Ершов, Б. Г., Akinshin, M. A., Гордеев, А. В., & Sukhov, N. L. (1986) · International Journal of Radiation Applications and Instrumentation Part C Radiation Physics and Chemistry · doi:10.1016/1359-0197(86)90139-6 · Cited by 4 · see citing works

The electronic theory of valency.

Sv, A. (1946) · PubMed · Cited by 3 · see citing works

Alpha-Particle Therapy for Acute Myeloid Leukemia

Jurcic, J. G. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.03.058 · Cited by 3 · see citing works

Radium Targets for the Reactor Production of Alpha-emitting Medical Radioisotopes

Copping, R., Mirzadeh, S., Stracener, D. W., Denton, D., Murphy, K., Wright, J., Hickman, E., & Marcus, C. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.03.049 · Cited by 3 · see citing works

Alpha-Particle Therapy for Acute Myeloid Leukemia

Jurcic, J. G. (2019) · Journal of medical imaging and radiation sciences · doi:10.1016/j.jmir.2019.11.063 · Cited by 3 · see citing works

?-Radioimmunotherapy with ²¹³Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma.

Teiluf, K. (2015) · mediaTUM (Technical University of Munich) · Cited by 2 · see citing works

Radiopharmaceutical Treatments for Cancer Therapy, Radionuclides Characteristics, Applications, and Challenges

Salih, S., Alkatheeri, A., Alomaim, W., & Elliyanti, A. (2022) · Molecules · doi:10.3390/molecules27165231 · Cited by 101 · see citing works

Dosimetry in Radiopharmaceutical Therapy

O’Donoghue, J. A., ZANZONICO, P. B., Humm, J. L., & Kesner, A. (2022) · Journal of Nuclear Medicine · doi:10.2967/jnumed.121.262305 · Cited by 91 · see citing works

Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals

Krasnovskaya, O. O., Abramchuk, D., Erofeev, A. S., Gorelkin, P. V., Kuznetsov, A. A., Shemukhin, A. A., & Beloglazkina, E. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119154 · Cited by 85 · see citing works

Alpha-Emitting Radionuclides: Current Status and Future Perspectives

Miederer, M., Benešová, M., Mamat, C., Kästner, D., Pretze, M., Michler, E., Brogsitter, C., Kotzerke, J., Kopka, K., Scheinberg, D. A., et al. (2024) · Pharmaceuticals · doi:10.3390/ph17010076 · Cited by 70 · see citing works

Alpha-peptide receptor radionuclide therapy using actinium-225 labeled somatostatin receptor agonists and antagonists

Shi, M., Jakobsson, V., Greifenstein, L., Khong, P.-L., Chen, X., Baum, R. P., & Zhang, J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.1034315 · Cited by 68 · see citing works

Radiotheranostic landscape: A review of clinical and preclinical development

Tran, H. H., Yamaguchi, A., & Manning, H. C. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-025-07103-7 · Cited by 67 · see citing works

Applications of radiocomplexes with thiosemicarbazones and bis(thiosemicarbazones) in diagnostic and therapeutic nuclear medicine

Parrilha, G. L., dos Santos, R. G., & Beraldo, H. D. O. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214418 · Cited by 62 · see citing works

PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

Fakiri, M. E., Geis, N. M., Ayada, N., Eder, M., & Eder, A.-C. (2021) · Cancers · doi:10.3390/cancers13163967 · Cited by 50 · see citing works

Equilibrium Thermodynamics of Macropa Complexes with Selected Metal Isotopes of Radiopharmaceutical Interest

Blei, M., Waurick, L., Reissig, F., Kopka, K., Stumpf, T., Drobot, B., Kretzschmar, J., & Mamat, C. (2023) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.3c01983 · Cited by 48 · see citing works

Peptide Receptor Radionuclide Therapy Targeting the Somatostatin Receptor: Basic Principles, Clinical Applications and Optimization Strategies

Bidakhvidi, N. A., Goffin, K. E., Dekervel, J., Baete, K., Nackaerts, K., Clément, P. M., Cutsem, E. V., Verslype, C., & Deroose, C. M. (2021) · Cancers · doi:10.3390/cancers14010129 · Cited by 48 · see citing works

Neuroendocrine tumor theranostics

Ichikawa, Y., Kobayashi, N., Takano, S., Kato, I., Endo, K., & Inoue, T. (2022) · Cancer Science · doi:10.1111/cas.15327 · Cited by 45 · see citing works

Bismuth chelation for targeted alpha therapy: Current state of the art

Franchi, S., Marco, V. D., & Tosato, M. (2022) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2022.06.002 · Cited by 41 · see citing works

Chelating the Alpha Therapy Radionuclides 225Ac3+ and 213Bi3+ with 18-Membered Macrocyclic Ligands Macrodipa and Py-Macrodipa

Hu, A., Brown, V., MacMillan, S. N., Radchenko, V., Yang, H., Wharton, L., Ramogida, C. F., & Wilson, J. J. (2021) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.1c03670 · Cited by 38 · see citing works

Radiometals in Imaging and Therapy: Highlighting Two Decades of Research

Sharma, S., & Pandey, M. K. (2023) · Pharmaceuticals · doi:10.3390/ph16101460 · Cited by 39 · see citing works

Targeted Alpha Therapy: All We Need to Know about 225Ac’s Physical Characteristics and Production as a Potential Theranostic Radionuclide

Jalloul, W., Ghizdovăţ, V., Stolniceanu, C. R., Ionescu, T. M., Grierosu, I. C., Păvăleanu, I., Moscalu, M., & Ştefănescu, C. (2023) · Pharmaceuticals · doi:10.3390/ph16121679 · Cited by 40 · see citing works

Alpha Atlas: Mapping global production of α-emitting radionuclides for targeted alpha therapy

Tosato, M., Favaretto, C., Kleynhans, J., Burgoyne, A. R., Gestin, J., van der Meulen, N. P., Jalilian, A. R., Köster, U., Asti, M., & Radchenko, V. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108990 · Cited by 38 · see citing works

Commercial and business aspects of alpha radioligand therapeutics

Ostuni, E., & Taylor, M. R. G. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2022.1070497 · Cited by 35 · see citing works

3p-C-NETA: A versatile and effective chelator for development of Al 18 F-labeled and therapeutic radiopharmaceuticals

Ahenkorah, S., Murce, E., Cawthorne, C., Ketchemen, J. P., Deroose, C. M., Cardinaels, T., Seimbille, Y., Fonge, H., Gsell, W., Bormans, G. M., et al. (2022) · Theranostics · doi:10.7150/thno.75336 · Cited by 34 · see citing works

Organotrifluoroborate enhances tumor targeting of fibroblast activation protein inhibitors for targeted radionuclide therapy

Liu, Y., Tang, H., Song, T., Xu, M., Chen, J., Cui, X.-Y., Han, Y., Li, Z., & Liu, Z. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06230-3 · Cited by 26 · see citing works

The Evolving Coordination Chemistry of Radiometals for Targeted Alpha Therapy

Grieve, M. L., & Paterson, B. M. (2021) · Australian Journal of Chemistry · doi:10.1071/ch21184 · Cited by 26 · see citing works

Antibody-based Radiopharmaceuticals as Theranostic Agents: An Overview

Sharma, R., Suman, S. K., & Mukherjee, A. (2022) · Current Medicinal Chemistry · doi:10.2174/0929867329666220607160559 · Cited by 23 · see citing works

H2ampa─Versatile Chelator for [203Pb]Pb2+, [213Bi]Bi3+, and [225Ac]Ac3+

Ingham, A., Wharton, L., Sayed, T. E., Southcott, L., McNeil, B. L., Ezhova, M. B., Patrick, B. O., Jaraquemada-Peláez, M. D. G., & Orvig, C. (2022) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.2c00636 · Cited by 21 · see citing works

Gamma counting protocols for the accurate quantification of 225Ac and 213Bi without the need for a secular equilibrium between parent and gamma-emitting daughter

Castillo, D., Saint‐Hubert, M. D., Ahenkorah, S., Vargas, C. S., Ooms, M., Struelens, L., & Koole, M. J. B. (2022) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-022-00174-z · Cited by 20 · see citing works

Advances in bismuth utilization for biomedical applications – From a bibliometric perspective

Gu, C., Zhu, S., & Gu, Z. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.215988 · Cited by 21 · see citing works

Towards Routine Clinical Use of Dosimetry in [177Lu]Lu-PSMA Prostate Cancer Radionuclide Therapy: Current Efforts and Future Perspectives

Alsadi, R., Djekidel, M., Bouhali, O., & O’Doherty, J. (2022) · Frontiers in Physics · doi:10.3389/fphy.2022.940677 · Cited by 19 · see citing works

Chemical Tools to Characterize the Coordination Chemistry of Radionuclides for Radiopharmaceutical Applications

Boros, E., Comba, P., Engle, J. W., Harriswangler, C., Lapi, S. E., Lewis, J. S., Mastroianni, S., Mirica, L. M., Platas‐Iglesias, C., Ramogida, C. F., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00641 · Cited by 20 · see citing works

A Radionuclide Generator of High-Purity Bi-213 for Instant Labeling

Ermolaev, S. V., Skasyrskaya, A. K., & Vasiliev, A. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13060914 · Cited by 17 · see citing works

In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions

van der Heide, C. D., Ma, H., Hoorens, M. W. H., Campeiro, J. D., Stuurman, D. C., de Ridder, C. M. A., Seimbille, Y., & Dalm, S. U. (2024) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-024-00283-x · Cited by 16 · see citing works

Preclinical investigation of [149Tb]Tb-DOTATATE and [149Tb]Tb-DOTA-LM3 for tumor-targeted alpha therapy

Mapanao, A. K., Busslinger, S. D., Mehta, A., Kegler, K., Favaretto, C., Grundler, P. V., Talip, Z., Köster, U., Johnston, K., Schibli, R., et al. (2025) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-07035-8 · Cited by 16 · see citing works

Sorption and desorption performance of La3+/Bi3+ by surface-modified activated carbon for potential application in medical 225Ac/213Bi generators

Zhu, H., Heinitz, S., Eyley, S., Thielemans, W., Binnemans, K., Mullens, S., & Cardinaels, T. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.142456 · Cited by 16 · see citing works

Construction of the Bioconjugate Py‐Macrodipa‐PSMA and Its In Vivo Investigations with Large 132/135La3+ and Small 47Sc3+ Radiometal Ions

Hu, A., Martin, K. E., Śmiłowicz, D., Aluicio‐Sarduy, E., Cingoranelli, S. J., Lapi, S. E., Engle, J. W., Boros, E., & Wilson, J. J. (2023) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202300457 · Cited by 15 · see citing works

“Cold” Somatostatin Analogs in Neuroendocrine Neoplasms: Decoding Mechanisms, Overcoming Resistance, and Shaping the Future of Therapy

Massironi, S., Albertelli, M., Hasballa, I., Paravani, P., Ferone, D., Faggiano, A., & Danese, S. (2025) · Cells · doi:10.3390/cells14040245 · Cited by 15 · see citing works

Radioimmunoconjugates in the age of modern immuno-oncology

Nasr, D., Kumar, P. A., Zerdan, M. B., Ghelani, G. H., Dutta, D., Graziano, S. L., & Lim, S. H. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121126 · Cited by 14 · see citing works

NGR-Based Radiopharmaceuticals for Angiogenesis Imaging: A Preclinical Review

Trencsényi, G., Enyedi, K. N., Mező, G., Halmos, G., & Képes, Z. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241612675 · Cited by 14 · see citing works

Novel candidate theranostic radiopharmaceutical based on strontium hexaferrite nanoparticles conjugated with azacrown ligand

Khabirova, S. Y., Aleshin, G. Y., Anokhin, E. O., Shchukina, A. A., Zubenko, A. D., Fedorova, O. A., Аверин, А. А., Trusov, L. A., & Kalmykov, S. N. (2023) · Dalton Transactions · doi:10.1039/d2dt03548k · Cited by 14 · see citing works

Clinical Experience with Targeted Alpha-Emitter Peptide Receptor Radionuclide Therapy (α-PRRT) for Somatostatin Receptor-Positive Neuroendocrine Tumors

Leupe, H., Cauwenbergh, M., Cleeren, F., Dekervel, J., Verslype, C., & Deroose, C. (2025) · Pharmaceuticals · doi:10.3390/ph18111608 · Cited by 14 · see citing works

Targeted Radium Alpha Therapy in the Era of Nanomedicine: In Vivo Results

Trencsényi, G., Csikos, C., & Képes, Z. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25010664 · Cited by 13 · see citing works

Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?

Kleynhans, J., Ebenhan, T., Cleeren, F., & Sathekge, M. M. (2024) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-024-06719-5 · Cited by 13 · see citing works

Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects

Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C., Al-Qahtani, M. H., Smith, C. J., & Sakr, T. M. (2025) · Cancers · doi:10.3390/cancers17183055 · Cited by 12 · see citing works

Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside

Jiao, X., Hong, H., & Cai, W. (2024) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.2006 · Cited by 11 · see citing works

In Vivo evaluation of newly synthesized 213Bi-conjugated alpha-melanocyte stimulating hormone (α-MSH) peptide analogues in melanocortin-1 receptor (MC1-R) positive experimental melanoma model

Kálmán-Szabó, I., Képes, Z., Fekete, A., Vágner, A., Nagy, G., Szücs, D., Gyuricza, B., Arató, V., Varga, J., Kárpáti, L., et al. (2023) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2023.115374 · Cited by 11 · see citing works

Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA**

Horváth, D., Vágner, A., Szikra, D., Trencsényi, G., Demitri, N., Guidolin, N., Maiocchi, A., Ghiani, S., Travagin, F., Giovenzana, G. B., et al. (2022) · Angewandte Chemie International Edition · doi:10.1002/anie.202207120 · Cited by 11 · see citing works

Advancements in Locoregional Therapies for Unresectable Intrahepatic Cholangiocarcinoma

O'Donnell, C., Majeed, U., Rutenberg, M. S., Croome, K. P., Poruk, K. E., Toskich, B. B., & Jin, Z. (2025) · Current Oncology · doi:10.3390/curroncol32020082 · Cited by 10 · see citing works

Rapid Elution of 226Th from a Two-Column 230U/226Th Generator with Diluted and Buffer Solutions

Ermolaev, S. V., Skasyrskaya, A. K., & Vasiliev, A. N. (2023) · Molecules · doi:10.3390/molecules28083548 · Cited by 10 · see citing works

Production of 225 Ac for medical application from 232 Th-metallic targets in Nb-shells irradiated with middle-energy protons

Ermolaev, S. V., Vasiliev, A. N., Lapshina, E. V., Kobtsev, A. A., & Zhuikov, B. L. (2024) · New Journal of Chemistry · doi:10.1039/d3nj05778j · Cited by 10 · see citing works

The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein

Lacerda, S., de Kruijff, R. M., & Djanashvili, K. (2025) · Molecules · doi:10.3390/molecules30061296 · Cited by 9 · see citing works

Recommendations on the Clinical Application and Future Potential of α-Particle Therapy: A Comprehensive Review of the Results from the SECURE Project

Iorio, V. D., Sarnelli, A., Boschi, S., Sansovini, M., Genovese, R. M., Ştefănescu, C., Ghizdovăţ, V., Jalloul, W., Young, J. D., Sosabowski, J. K., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18101578 · Cited by 9 · see citing works

Selective separation of Bi3+ from La3+/Ac3+ by sorption on sulfonated carbon materials for use in an inverse 225Ac/213Bi radionuclide generator: Batch and column tests

Zhu, H., Heinitz, S., Eyley, S., Thielemans, W., Binnemans, K., Mullens, S., & Cardinaels, T. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.143416 · Cited by 9 · see citing works

225 Ac/ 213 Bi radionuclide generators for the separation of 213 Bi towards clinical demands

Zhu, H., Heinitz, S., Binnemans, K., Mullens, S., & Cardinaels, T. (2024) · Inorganic Chemistry Frontiers · doi:10.1039/d4qi00326h · Cited by 9 · see citing works

In vivo investigation of Gallium-68 and Bismuth-205/206 labeled beta cyclodextrin for targeted alpha therapy of prostaglandin E2 receptor-expressing tumors in mice

Csige, K., Szabó, J. P., Kálmán-Szabó, I., Dénes, N., Szikra, D., Képes, Z., Opposits, G., Méhes, G., Kertész, I., Fenyvesi, F., et al. (2022) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2022.122132 · Cited by 9 · see citing works

Radiation Dosimetry in Theranostics: A Review

ZANZONICO, P. B. (2025) · Journal of Nuclear Medicine Technology · doi:10.2967/jnmt.125.270852 · Cited by 8 · see citing works

Cell Senescence and the DNA Single-Strand Break Damage Repair Pathway

Sarma, P. A. P., Abbadie, C., de Launoit, Y., & Cleri, F. (2024) · DNA · doi:10.3390/dna4040036 · Cited by 8 · see citing works

Targeted bismuth-based materials for cancer

Batool, A., Kopp, I., Kubeil, M., Bachmann, M. P., Andrews, P. C., & Stephan, H. (2025) · Dalton Transactions · doi:10.1039/d5dt00163c · Cited by 6 · see citing works

Solid-phase extraction of 225Ac using ion-imprinted resin and 243Am as a radioactive tracer for internal dosimetry and incorporation measurements

Cusnir, R., Froidevaux, P., Carbonez, P., & Straub, M. (2022) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339421 · Cited by 7 · see citing works

Production and Quality Control of Actinium-225 Radiopharmaceuticals

INTERNATIONAL ATOMIC ENERGY AGENCY (2024) · International Atomic Energy Agency eBooks · doi:10.61092/iaea.95h3-2ji2 · Cited by 7 · see citing works

Radiolabeled Probes from Derivatives of Natural Compounds Used in Nuclear Medicine

Tesse, G., Tolomeo, A. M., Filippis, B. D., & Giampietro, L. (2024) · Molecules · doi:10.3390/molecules29174260 · Cited by 6 · see citing works

Somatostatin receptor‐linked α‐particle therapy in neuroendocrine tumours

Navalkissoor, S., & Grossman, A. B. (2024) · Journal of Neuroendocrinology · doi:10.1111/jne.13463 · Cited by 6 · see citing works

Rigid H 4 OCTAPA derivatives as model chelators for the development of Bi( iii )-based radiopharmaceuticals

Lucio‐Martínez, F., Esteban‐Gómez, D., Valencia, L., Horváth, D., Szücs, D., Fekete, A., Szikra, D., Tircsó, G., & Platas‐Iglesias, C. (2023) · Chemical Communications · doi:10.1039/d2cc06876a · Cited by 6 · see citing works

Bi-HPDO3A as a novel contrast agent for X-ray computed tomography

Rizzo, R., Capozza, M., Carrera, C., & Terreno, E. (2023) · Scientific Reports · doi:10.1038/s41598-023-43031-y · Cited by 6 · see citing works

Cyclotron production of a 204Bi/204mPb generator by 24 MeV proton irradiation of natural Pb foil targets

Blanco, J. R., Edwards, T., Irvin, T. E., Kleinfeldt, C., Lapi, S. E., & Severin, G. W. (2025) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2025.112147 · Cited by 5 · see citing works

The application of radionuclide therapy for breast cancer

Musket, A., Davern, S. M., Elam, B. M., Musich, P. R., Moorman, J. P., & Jiang, Y. (2024) · Frontiers in Nuclear Medicine · doi:10.3389/fnume.2023.1323514 · Cited by 5 · see citing works

Gamma radiation effects on AG MP-50 cation exchange resin and sulfonated activated carbon for bismuth-213 separation

Zhu, H., Heinitz, S., Eyley, S., Thielemans, W., Derveaux, E., Adriaensens, P., Binnemans, K., Mullens, S., & Cardinaels, T. (2023) · RSC Advances · doi:10.1039/d3ra06130b · Cited by 5 · see citing works

An overview of the role of radionuclides in targeted cancer treatment: application of biomarkers for patient selection and developments to improve treatment efficacy

Smith, T. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1572118 · Cited by 4 · see citing works

Astatine-211-Labeled Therapy Targeting Amino Acid Transporters: Overcoming Drug Resistance in Non-Small Cell Lung Cancer

Feng, S., Hisada, K., Yorifuji, H., Shirakami, Y., & Kaneda‐Nakashima, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110736 · Cited by 4 · see citing works

Current and future perspectives on radioligand therapy in advanced prostate cancer

Ahmed, B. S., & Ravi, P. K. (2026) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251409047 · Cited by 4 · see citing works

Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective

Maithania, H. V., John, R., Painoori, R., monpara, J., Swaminathan, S., & Kalhapure, R. S. (2026) · AAPS PharmSciTech · doi:10.1208/s12249-026-03346-1 · Cited by 4 · see citing works

225Aс/213Bi generator for direct synthesis of 213Bi-labeled bioconjugates

Ermolaev, S. V., Vasiliev, A. N., Skasyrskaya, A. K., Lapshina, E. V., Khaliullina, D. R., & Libanova, O. N. (2024) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2024.108975 · Cited by 4 · see citing works

52Mn-labelled Beta-cyclodextrin for Melanoma Imaging: A Proof-of-concept Preclinical Study

Képes, Z., Szabó, J. P., Kálmán-Szabó, I., Sass, T., Esze, R., Opposits, G., Jószai, I., Szikra, D., Fenyvesi, F., Hajdu, I., et al. (2024) · In Vivo · doi:10.21873/invivo.13735 · Cited by 4 · see citing works

Evaluation of the therapeutic efficacy of 213Bi-labelled DOTA-conjugated alpha-melanocyte stimulating hormone peptide analogues in melanocortin-1 receptor positive preclinical melanoma model

Csikos, C., Képes, Z., Fekete, A., Vágner, A., Nagy, G., Gyuricza, B., Arató, V., Kárpáti, L., Mándity, I. M., Bruchertseifer, F., et al. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.123344 · Cited by 4 · see citing works

Production of 230Pa as a Source for Medical Radionuclides 230U and 226Th Including Isolation by Liquid–liquid Extraction

Vasiliev, A. N., Ermolaev, S. V., Lapshina, E. V., Bravo, M. G., & Skasyrskaya, A. K. (2022) · Solvent Extraction and Ion Exchange · doi:10.1080/07366299.2022.2088059 · Cited by 4 · see citing works

Advances in Molecular Imaging for Neuroendocrine Neoplasms

Girod, B., & Prasad, V. (2025) · Cancers · doi:10.3390/cancers17122013 · Cited by 3 · see citing works

Radiotheranostics with high-LET α-particle and auger Electron emitters: A coordination chemistry perspective

Munekane, M., Fuchigami, T., & Ogawa, K. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218173 · Cited by 3 · see citing works

Quality Assurance and Quality Control Methods in Radiopharmacy

Kılçar, A. Y. (2023) · Nuclear Medicine Seminars · doi:10.4274/nts.galenos.2023.0010 · Cited by 3 · see citing works

Gas-chemical approach to 225Ac/213Bi radionuclide generator for medical application

Zobnin, V., Zhuikov, B. L., Vasiliev, A. N., & Polnyakov, G. A. (2024) · Applied Radiation and Isotopes · doi:10.1016/j.apradiso.2024.111581 · Cited by 3 · see citing works

The Emerging Potential of Lead-212 Theranostics

Plichta, K. A., & Buatti, J. M. (2025) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2024.11.001 · Cited by 3 · see citing works

Alpha particle microdosimetry calculations using a shallow neural network

Wagstaff, P., Gabiña, P. M., Mínguez, R., & Roeske, J. C. (2022) · Physics in Medicine and Biology · doi:10.1088/1361-6560/ac499c · Cited by 3 · see citing works

Radiopharmaceuticals for Therapy

Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_17 · Cited by 3 · see citing works

Study on the sorption and desorption behavior of La 3+ and Bi 3+ by bis(2-ethylhexyl)phosphate modified activated carbon

Zhu, H., Heinitz, S., Binnemans, K., Mullens, S., & Cardinaels, T. (2024) · RSC Advances · doi:10.1039/d4ra06276k · Cited by 2 · see citing works

Preclinical evaluation of Manganese-52 labelled cyclodextrin: a prostaglandin E2 affine imaging probe

Dienes, R. A., Komor, L. A., Szabó, J. P., Berzi, A., Emri, M., Szikra, D., Fekete, A., Opposits, G., Jószai, I., Kertész, I., et al. (2025) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2025.107344 · Cited by 2 · see citing works

A Cursory Gaze at Solitary Radiopharmaceutical Chelators Incorporating Macrocyclic and Acyclic Moieties

Ahenkorah, S., & Ramdhani, D. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121508 · Cited by 2 · see citing works

Medicinal applications of bismuth(III): from antimicrobial to anticancer

Lok, J. G.-T., Chan, C.-L., Hao, Q., Li, H., & Sun, H. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113299 · Cited by 2 · see citing works

Complexes of DOTAM with d 10 Divalent Metal Ions: X-ray Diffraction and NMR Studies in Solution and the Solid State

Obuch, J., Cı́sařová, I., Czernek, J., Brus, J., & Hermann, P. (2026) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.6c01226 · Cited by 2 · see citing works

Targeted Alpha Therapy in Cancer Management: Therapeutic Prospects of Nuclear Medicine in Oncology

Mdanda, S., Mdlophane, A. H., Ndlovu, H., Ramonaheng, K., Qebetu, M., Mahapane, J., Kgatle, M., Mzizi, Y. V., Sebatana, R., Cele, Z. E. D., et al. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2023_195 · Cited by 2 · see citing works

State of the art and future perspectives of new radionuclides in Nuclear Medicine. Part II

Sancho, L., Roteta, A., Torres, I., de Arcocha, M., Ramos-Membrive, R., Domínguez, M. L., Rosales, J. J., Prieto, E., & Quincoces, G. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) · doi:10.1016/j.remnie.2025.500128 · Cited by 2 · see citing works

Targeted alpha therapy of ovarian cancer with 212Pb-labeled anti-PTK7 antibody: On-site 212Pb production and preclinical insights

Berckmans, Y., Wouters, R., Raskovic-Lovre, Z., Mechelen, S. V., Lindland, K., Bønsdorff, T. B., Coosemans, A., & Cleeren, F. (2025) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2025.109570 · Cited by 2 · see citing works

Insights into recent preclinical studies on labelled cyclodextrin-based imaging probes: Towards a novel oncological era

Képes, Z., Hajdu, I., Fenyvesi, F., & Trencsényi, G. (2023) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2023.122978 · Cited by 2 · see citing works

Prospects for the Use of Bismuth Nanoparticles and Its Compounds in Biomedicine

Rudyy, A. V., Fronya, A. A., & Zavestovskaya, I. N. (2023) · Physics of Atomic Nuclei · doi:10.1134/s106377882311039x · Cited by 2 · see citing works

The LUTIA trial: a small step for PRRT, a giant leap for intra-arterial radionuclide therapy trial methodology

Deroose, C. M. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06581-x · Cited by 2 · see citing works

A Preliminary Study of Spherical Surface-Modified Carbon Materials for Potential Application in La3+ (Ac3+) and Bi3+ Separation

Zhu, H., Heinitz, S., Binnemans, K., Mullens, S., & Cardinaels, T. (2024) · ACS Omega · doi:10.1021/acsomega.4c05457 · Cited by 1 · see citing works

Preclinical characterization of 3p-C-DEPA-NCS and 3p-C-DEPA-TFP-PEG4 as potential Actinium-225 bifunctional chelators using DOTA-NCS and macropa-NCS as benchmarks

Ketchemen, J. P., Ahenkorah, S., Nwangele, E., Malaza, S. S. P., Ooms, M., Cardinaels, T., Leekens, S., Cleeren, F., & Fonge, H. (2025) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-025-00408-w · Cited by 1 · see citing works

Theranostic and Radionuclide-based Treatment Approaches for Radioiodine-refractory Thyroid Cancer: From Biology to Clinical Application

Arawker, M. H., Habibullah, F., Fu, L., Baral, S., & Qiu, X. (2026) · Molecular Imaging and Biology · doi:10.1007/s11307-026-02082-z · Cited by 1 · see citing works

Theranostics and Molecular-targeted Endo-radiotherapy: The Current Landscape and Future Directions

Nazar, A. K., & Basu, S. K. (2025) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000006120 · Cited by 1 · see citing works

Biodistribution of 213Bi–Metallothionein and 213Bi–IgG in Intact Mice

Петриев, В. М., Тищенко, В. К., Шегай, П. В., Иванов, С. А., & Каприн, А. Д. (2022) · Physics of Atomic Nuclei · doi:10.1134/s1063778822090253 · Cited by 1 · see citing works

Production and Supply of Raw Materials for Radiometals used in Radionuclide Imaging and Therapy in Korea

Seo, S., & Seo, Y. (2025) · Nuclear Medicine and Molecular Imaging · doi:10.1007/s13139-025-00907-3 · Cited by 1 · see citing works

Boosting Bismuth(III) Complexation for Targeted α‐Therapy (TAT) Applications with the Mesocyclic Chelating Agent AAZTA**

Horváth, D., Vágner, A., Szikra, D., Trencsényi, G., Demitri, N., Guidolin, N., Maiocchi, A., Ghiani, S., Travagin, F., Giovenzana, G. B., et al. (2022) · Angewandte Chemie · doi:10.1002/ange.202207120

Chemistry of Therapeutic Radionuclides

Vallabhajosula, S. (2023) · Springer eBooks · doi:10.1007/978-3-031-23205-3_18

Radiopharmaceutical Therapy: Strategy for Management to Optimize Patient Care – A Case Report

Ding, L., Smith, K. S., Iandoli, M., Laurie, F., Bradford, C., LaRosa, S., Khalifeh, A., Liu, F., Kuo, I., Razzaq, M., et al. (2024) · Medical Research Archives · doi:10.18103/mra.v12i4.5218

Calculation of alpha particle single-event spectra using a neural network

Alkhani, L., Luce, J., Gabiña, P. M., & Roeske, J. C. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1394671

Pursuing theranostics: a multimodal architecture approach

Bender, A. A., Holiski, C. K., Embree, M. F., Hennkens, H. M., Klaehn, J. R., Lundgreen, E., Roberts, A. G., Zalupski, P. R., & Mastren, T. (2024) · Sensors & Diagnostics · doi:10.1039/d4sd00221k

Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte II

Sancho, L., Roteta, A., Torres, I., de Arcocha, M., Ramos-Membrive, R., Domínguez, M. L., Rosales, J. J., Prieto, E., & Quincoces, G. (2025) · Revista Española de Medicina Nuclear e Imagen Molecular · doi:10.1016/j.remn.2025.500128

Use of 225Ac and 213Bi radioisotopes in targeted alpha therapy for cancer treatment

Mayorga‐Martino, V., & Puyen, T. E. V. (2022) · Portal de Revistas PUCP (N/A)

Targeted α therapy with 213Bi and 225Ac

Kellerbauer, A., Bruchertseifer, F., Malmbeck, R., & Morgenstern, A. (2020) · Journal of Physics Conference Series · doi:10.1088/1742-6596/1643/1/012205 · Cited by 4 · see citing works

Targeted alpha therapy with 213Bi.

Morgenstern, A., Bruchertseifer, F., & Apostolidis, C. (2011) · Current Radiopharmaceuticalse · doi:10.2174/1874471011104040295 · Cited by 58 · see citing works

Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy: Current Supply, Application Barriers, and Future Prospects

Nawar, M. F., Selim, A. A., Essa, B. M., El-Daoushy, A. F., Swidan, M. M., Chambers, C., Al-Qahtani, M. H., Smith, C. J., & Sakr, T. M. (2025) · Cancers · doi:10.3390/cancers17183055 · Cited by 12 · see citing works

Targeted alpha therapy with bismuth‐213 and actinium‐225: Meeting future demand

Bruchertseifer, F., Kellerbauer, A., Malmbeck, R., & Morgenstern, A. (2019) · Journal of Labelled Compounds and Radiopharmaceuticals · doi:10.1002/jlcr.3792 · Cited by 68 · see citing works